Expert view: Are you ready for next generation therapeutic antibodies?

The ‘developability’ of such antibodies depends on certain criteria, such as stability, titre, activity, affinity and aggregation level. Of late, another challenge that is on the rise globally is the need for high-throughput methods for faster and cheaper antibody production.

There are many technologies in today’s market aiding such research, but not all analytical platforms are created equal. The successful development of a bsAb depends, at least in part, on selection of the right analytical toolbox. One such platform that delivers on multiple developability requirements is the Octet^® platform. This provides real-time analysis of biomolecular interactions with a robust and easy to develop on Dip and Read^™ platform technology. Crude sample compatibility and fluidics-free architecture provides the fast time to results demanded by current and next generation antibodies. The ability to analyse up to 96 antibody samples within minutes, as seen with the Octet HTX system, facilitates high-throughput screening of bsAb leads for developability, increasing analytical productivity. Samples analysed on Octet systems can also be reused for further analysis, conserving precious samples, decreasing costs and maximising process economy. Thus, by selecting the right analytical platform, many of the challenges in developing a molecule as complex as a bsAb can be overcome.